Clinical trial · Interventional
Tau PET Outcomes With Anti-amyloid Immunotherapies
Study of Tau PET Outcomes in Patients Receiving Anti-amyloid Immunotherapies
NCT06723015CI-TRIAL-00097370enrolling by invitationPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Alzheimer Disease | — | UNRESOLVED | — |
| Cognitive Impairment, Mild | — | UNRESOLVED | — |
| Dementia, Mild | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-AV-1451 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control Group
- description
- Untreated historical controls enrolled in Mayo Clinic Study of Aging (IRB 14-004401), Mayo Alzheimer's Disease Research Center (IRB 712-98), and Brain Amyloid Imaging with Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia (IRB 08-005553).
- type
- EXPERIMENTAL
- label
- Treatment Group
- description
- Subjects with a diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease and amyloid positive, who are starting anti-amyloid immunotherapy.
- interventionNames
- Drug: 18F-AV-1451
Primary outcomes (1)
- measure
- Change in tau PET Standardized Uptake Value (SUVR)
- timeFrame
- Baseline, 18 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria * Age 50-90 years * Male or female * Mild cognitive impairment due to AD or mild AD * Amyloid positive via CSF or PET * Meets other eligibility criteria for anti-amyloid immunotherapy * Subject or delegate provides informed consent Exclusion Criteria * Subjects unable to lie down without moving for 10 minutes. * Women who are pregnant or cannot stop breast feeding for 24 hours. * Claustrophobic patients unable to tolerate the scans (no sedation can be offered).
References
Publications (0)
Data not yet available
No reference posted for this study.